Clinical Trials: Lymphomas

California

Duarte; City of Hope
COG A003: Phase I trial and pharmacokinetic study of arsenic trioxide in pediatric patients with refractory leukemia or lymphoma

Duarte; City of Hope
Prospective Chart Review for Data Inclusion into Sentinel Node Working Group

Duarte; City of Hope
Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation, AnorMED Protocol, AMD3100-CUP001

Duarte; City of Hope
Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Volunteer Donors for Use in T Cell Program

Duarte; City of Hope
A Phase I/II Study of VELCADE in Combination with Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma

Indiana

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase III: Multicenter Study to Investigate Safety and Efficacy of Treanda in Patients with Indolent NHL Who are Refractory to Rituximab

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II: At Least One Prior Treatment Randomized Open Label Comparison of Rituxan plus study drug to Rituxan Alone for Relapsed Follicular B-cell Lymphoma with at least 1 prior treatment.

New York

Lake Success; Biomedical Research Alliance of New York
Diffuse Large B-Cell Lymphoma - Adults

New York; Mount Sinai Medical Center
A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas

New York; Columbia-Presbyterian Medical Center
Study of donor leukocyte infusions in patients with recurrent or persistent hematological malignancies after allogeneic bone marrow transplantation.

New York; Columbia-Presbyterian Medical Center
Study of the use of peripheral blood stem cells for allogeneic transplantation (PBSCT) in patients with advanced hematological malignancies at increased risk of relapse or transplant-related mortality

New York; Columbia-Presbyterian Medical Center
Study of standard chemotherapy and radiotherapy before allogeneic stem cell transplantation

New York; Columbia-Presbyterian Medical Center
Study of tandem high dose chemotherapy and autologous blood stem cell transplantation for lymphoma

New York; Columbia-Presbyterian Medical Center
Study of transplantation using umbilical cord and placental blood

New York; Mount Sinai School of Medicine
Lymphoma - Treatment of Severe Thrombocytopenia (low platelet levels)

Ohio

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
(ANHL06P1) A Phase I/II Pilot Study of Ifosfamide, Carboplatin, Etoposide, and Monoclonal Antibody SGN-30 in Pediatric Patients with CD30-Positive Recurrent Anaplastic Large Cell Lymphoma

Texas

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Central Nervous System Lymphoma

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Mantle Zone Lymphoma

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Lymphoma Of The Gastrointestinal Tract

Virginia

Charlottesville; University of Virginia
Pediatric Patients Sough for the Treatment of Disseminated or Localized Lymphoblastic Lymphoma

International

Greenfield Park, QC, Canada; Research Site:
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Quebec City, QC, Canada; Research Site:
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Hillerød, Denmark; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

København, Denmark; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lille, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Montpellier, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Paris, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Pessac, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Pierre Benite, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Rennes, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Rouen, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Bergen, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Oslo, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Stavanger, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Tromsø, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Trondheim, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Eskilstuna, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Falun, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Halmstad, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Huddinge, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Jonkoping, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Karlstad, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Linkoeping, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lulea, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lund, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Malmoe, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Oerebro, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Stockholm, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Sundsvall, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Umea, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Uppsala, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Västerås, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Vaxjo, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Visby, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma